356 related articles for article (PubMed ID: 26019189)
1. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Bossuyt V; Provenzano E; Symmans WF; Boughey JC; Coles C; Curigliano G; Dixon JM; Esserman LJ; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Viale G; Cameron D;
Ann Oncol; 2015 Jul; 26(7):1280-91. PubMed ID: 26019189
[TBL] [Abstract][Full Text] [Related]
2. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
Bossuyt V; Spring L
Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
[TBL] [Abstract][Full Text] [Related]
3. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
Bossuyt V; Symmans WF
Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
[TBL] [Abstract][Full Text] [Related]
4. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
Pfob A; Cai L; Schneeweiss A; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten MM; Sidey-Gibbons C; Wallwiener M; Golatta M; Heil J
Ann Surg Oncol; 2024 Feb; 31(2):957-965. PubMed ID: 37947974
[TBL] [Abstract][Full Text] [Related]
5. Distinct Prognosis of Minimal Residual Disease According to Breast Cancer Subtype in Patients with Breast or Nodal Pathologic Complete Response After Neoadjuvant Chemotherapy.
Go J; Ahn JH; Park JM; Choi SB; Kim JY; Park HS; Kim SI; Park BW; Park S
Ann Surg Oncol; 2023 Nov; 30(12):7060-7068. PubMed ID: 37537485
[TBL] [Abstract][Full Text] [Related]
6. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Bossuyt V
Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
[TBL] [Abstract][Full Text] [Related]
7. Pathological measurement and staging of residual breast cancer after neoadjuvant chemotherapy.
Harter D; O'Connor SM; Hertel JD; Calhoun BC
Histopathology; 2023 Sep; 83(3):453-464. PubMed ID: 37256703
[TBL] [Abstract][Full Text] [Related]
8. Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
Kozak MM; Jacobson CE; von Eyben R; Pollom EL; Telli M; Horst KC
J Natl Compr Canc Netw; 2018 Jul; 16(7):845-850. PubMed ID: 30006427
[No Abstract] [Full Text] [Related]
9. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
[TBL] [Abstract][Full Text] [Related]
10. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
[TBL] [Abstract][Full Text] [Related]
12. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
[TBL] [Abstract][Full Text] [Related]
15. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
Viale G
Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.
Wong SM; Almana N; Choi J; Hu J; Gagnon H; Natsuhara K; Shen AH; DeSantis S; Dominici L; Golshan M; Weiss A; Bellon J; Mittendorf EA; King TA
Ann Surg Oncol; 2019 Oct; 26(11):3502-3509. PubMed ID: 31228134
[TBL] [Abstract][Full Text] [Related]
17. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
18. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer, neoadjuvant chemotherapy and residual disease.
Chávez-MacGregor M; González-Angulo AM
Clin Transl Oncol; 2010 Jul; 12(7):461-7. PubMed ID: 20615822
[TBL] [Abstract][Full Text] [Related]
20. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement.
Guerini-Rocco E; Botti G; Foschini MP; Marchiò C; Mastropasqua MG; Perrone G; Roz E; Santinelli A; Sassi I; Galimberti V; Gianni L; Viale G
Tumori; 2022 Jun; 108(3):196-203. PubMed ID: 34918596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
